Table 4 |
||
|
Differences in clinical and serological characteristics of PR3/MPO-ANCA positive antithyroid DIDs |
||
| Antithyroid drug-induced vasculitides (n = 4) |
Antithyroid drug-induced LLD (n = 12) |
|
|
|
||
| Age, years (range) |
35 ± 6 (20–40) |
30 ± 8 (25–52) |
| Female |
3 (75) |
12 (100) |
| Graves' disease |
4 (100) |
9 (75) |
| Hashimoto thyroiditis |
0 |
3 (25) |
| Florid hyperthyroidism |
4 (100) |
3 (25) |
| Relapse of hyperthyroidism |
2 (50) |
4 (33.3) |
| Antimicrosomal Ab |
3 (75) |
10 (83.3) |
| Antithyroid drug therapy, months |
21 ± 6 |
18 ± 7 |
| Months between first complaints and ANCA detection |
3 ± 1.5 |
2 ± 1 |
| Propylthiouracil |
2 (50) |
10 (83.3) |
| Methimazole |
2 (50) |
2 (16.7) |
| Renal manifestations |
2 (50) |
1 (8.3) |
| Lung manifestations |
3 (75) |
0 |
| Skin manifestations |
0 |
10 (83.3) |
| PANCA |
3 (75) |
12 (100) |
| CANCA |
1 (25) |
0 |
| MPO-ANCA (U/ml) |
65 ± 20 |
53 ± 15 |
| PR3-ANCA (U/ml) |
44 |
- |
| ANA |
0 |
8 (66.6) |
| aCL IgG, IgM |
0 |
9 (75) |
| Anti-β2 GP I IgG, IgM |
0 |
4 (33.3) |
| Cryoglobulinemia |
0 |
3 (25) |
| Low C4 (<0.1 g/l) |
0 |
3 (25) |
| High CR-P (>10 mg/l) |
4 (100) |
4 (33.3) |
| Leucopenia (<3 × l09/l) |
0 |
2 (16.7) |
|
|
||
|
All values represent either numbers of patients (%), or mean ± standard deviation. Ab, antibodies; aCL, anticardiolipin antibodies; ANA, antinuclear antibodies; anti-β2 GP I, anti-beta 2 glycoprotein I; cANCA, cytoplasmic antineutrophil cytoplasmic antibodies; CR-P, C reactive protein; LLD, lupus-like disease; MPO, myeloperoxidase; PR3, proteinase 3; pANCA, perinuclear antineutrophil cytoplasmic antibodies. |
||
|
Bonaci-Nikolic et al. Arthritis Research & Therapy 2005 7:R1072 doi:10.1186/ar1789 |
||
